KRAS and cancer: As cancer risk profiling becomes increasingly common, and as an increasing number of treatment decisions are linked to genotyping results, e.g., erlotinib used for the treatment of lung cancer patients with EGFR mutations [25], or cetuximab therapy for colon patients lacking KRAS mutations [26] elucidating the roles ethnic differences have in the clinical management of cancer will entail a better understanding the relationship between ethnicity and predictive markers.